MOUNTAIN VIEW, Calif., June 24, 2025 - Iridex Corporation (Nasdaq: IRIX), a leading provider of laser-based medical systems, has announced the enrollment of the first patient in the DAME Trial, an independent, investigator-led study in the UK. This clinical trial aims to evaluate the effectiveness, safety, and cost-efficiency of incorporating MicroPulse® laser technology alongside anti-VEGF therapy for patients with severe diabetic macular edema $(DME.AU)$. The study, led by Professor Noemi Lois at Queen's University Belfast, seeks to determine whether adding subthreshold MicroPulse treatments can reduce the frequency of anti-VEGF injections while maintaining visual outcomes. The trial involves 264 participants across at least 20 clinical sites in the UK. Results of the study are yet to be presented, as the trial is in its early stages.